Fotios (Frank) Michelis, MD, PhD

Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre

Keywords: immune reconstitution, late effects, acute myeloid leukemia (AML), allogeneic stem cell/bone marrow transplant

Reduced Intensity Conditioning and Dual T-Lymphocyte Suppression with Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis In Haploidentical Stem Cell Transplants For Hematological Malignancies.
Biol Blood Marrow Transplant. 2018 Jul 12;:
Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, Kim DDH, Lipton JH, Kumar R, Messner H, Viswabandya A
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Ann Hematol. 2018 Jun 11;:
Khalil MMI, Messner HA, Lipton JH, Kim DD, Viswabandya A, Thyagu S, Deotare U, Michelis FV
Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients.
Biol Blood Marrow Transplant. 2018 Apr 18;:
Coomes EA, Wolfe Jacques A, Michelis FV, Kim DDH, Thyagu S, Viswabandya A, Lipton JH, Messner HA, Deotare U
Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant.
Eur Respir J. 2018 May;51(5):
Hirama T, Brode SK, Beswick J, Law AD, Lam W, Michelis FV, Thyagu S, Viswabandya A, Lipton JH, Messner HA, Kim DDH, Marras TK
Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation.
Bone Marrow Transplant. 2018 Mar;53(3):361-365
Deotare U, Atenafu EG, Loach D, Michelis FV, Kim DD, Thyagu S, Lipton JH, Messner HA, Viswabandya A
Therapeutic efficacy of azathioprine in addition to prednisone-based regimens as first-line chronic graft-versus-host disease treatment.
Bone Marrow Transplant. 2018 Mar;53(3):334-338
Uhm J, Shin E, Michelis FV, Thyagu S, Viswabandya A, Lipton JH, Messner HA, Kim DDH
Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience.
Eur J Haematol. 2018 Mar;100(3):308-314
Aljasem HA, Messner HA, Lipton JH, Kim DDH, Viswabandya A, Thyagu S, Deotare U, Michelis FV
Impact of comorbidities constituting the HCT-CI score on the outcome of patients undergoing allogeneic HCT for AML.
Eur J Haematol. 2017 Nov 23;:
Khalil MMI, Lipton JH, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, Viswabandya A, Messner HA, Michelis FV
Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1.
Eur J Haematol. 2017 May 27;:
Bourlon C, Lipton JH, Deotare U, Gupta V, Kim DD, Kuruvilla J, Viswabandya A, Thyagu S, Messner HA, Michelis FV
Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data.
Eur J Haematol. 2017 Apr 27;:
Poch Martell M, Hamad N, Shin E, Moon JH, Sohn SK, Uhm J, Michelis FV, Viswabandya A, Lipton JH, Messner HA, Kim DDH

Pages
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Assistant Professor, Department of Medicine, University of Toronto